The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity

Jose Maria Moreno-Navarrete, Victoria Catalan, Lauren Whyte, Adenis Diaz-Arteaga, Rafael Vazquez-Martinez, Fernando Rotellar, Rocio Guzman, Javier Gomez-Ambrosi, Marina R. Pulido, Wendy R. Russell, Monica Imbernon, Ruth A. Ross, Maria M. Malagon, Carlos Dieguez, Jose Manuel Fernandez-Real, Gema Fruehbeck, Ruben Nogueiras

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

GPR55 is a putative cannabinoid receptor, and l-α-lysophosphatidylinositol (LPI) is its only known endogenous ligand. We investigated 1) whether GPR55 is expressed in fat and liver; 2) the correlation of both GPR55 and LPI with several metabolic parameters; and 3) the actions of LPI on human adipocytes. We analyzed CB1, CB2, and GPR55 gene expression and circulating LPI levels in two independent cohorts of obese and lean subjects, with both normal or impaired glucose tolerance and type 2 diabetes. Ex vivo experiments were used to measure intracellular calcium and lipid accumulation. GPR55 levels were augmented in the adipose tissue of obese subjects and further so in obese patients with type 2 diabetes when compared with nonobese subjects. Visceral adipose tissue GPR55 correlated positively with weight, BMI, and percent fat mass, particularly in women. Hepatic GPR55 gene expression was similar in obese and type 2 diabetic subjects. Circulating LPI levels were increased in obese patients and correlated with fat percentage and BMI in women. LPI increased the expression of lipogenic genes in visceral adipose tissue explants and intracellular calcium in differentiated visceral adipocytes. These findings indicate that the LPI/GPR55 system is positively associated with obesity in humans.

Original languageEnglish
Pages (from-to)281-291
Number of pages11
JournalDiabetes
Volume61
Issue number2
Early online date16 Feb 2011
DOIs
Publication statusPublished - Feb 2012

Keywords

  • type-2 diabetes-mellitus
  • human adipose-tissue
  • cannabinoid receptor
  • endocannabinoid system
  • energy-balance
  • sexual dimorphism
  • gene-expression
  • gastric bypass
  • ovarian-cancer
  • GPR55

Cite this

Maria Moreno-Navarrete, J., Catalan, V., Whyte, L., Diaz-Arteaga, A., Vazquez-Martinez, R., Rotellar, F., ... Nogueiras, R. (2012). The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes, 61(2), 281-291. https://doi.org/10.2337/db11-0649

The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. / Maria Moreno-Navarrete, Jose; Catalan, Victoria; Whyte, Lauren; Diaz-Arteaga, Adenis; Vazquez-Martinez, Rafael; Rotellar, Fernando; Guzman, Rocio; Gomez-Ambrosi, Javier; Pulido, Marina R.; Russell, Wendy R.; Imbernon, Monica; Ross, Ruth A.; Malagon, Maria M.; Dieguez, Carlos; Manuel Fernandez-Real, Jose; Fruehbeck, Gema; Nogueiras, Ruben.

In: Diabetes, Vol. 61, No. 2, 02.2012, p. 281-291.

Research output: Contribution to journalArticle

Maria Moreno-Navarrete, J, Catalan, V, Whyte, L, Diaz-Arteaga, A, Vazquez-Martinez, R, Rotellar, F, Guzman, R, Gomez-Ambrosi, J, Pulido, MR, Russell, WR, Imbernon, M, Ross, RA, Malagon, MM, Dieguez, C, Manuel Fernandez-Real, J, Fruehbeck, G & Nogueiras, R 2012, 'The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity', Diabetes, vol. 61, no. 2, pp. 281-291. https://doi.org/10.2337/db11-0649
Maria Moreno-Navarrete J, Catalan V, Whyte L, Diaz-Arteaga A, Vazquez-Martinez R, Rotellar F et al. The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes. 2012 Feb;61(2):281-291. https://doi.org/10.2337/db11-0649
Maria Moreno-Navarrete, Jose ; Catalan, Victoria ; Whyte, Lauren ; Diaz-Arteaga, Adenis ; Vazquez-Martinez, Rafael ; Rotellar, Fernando ; Guzman, Rocio ; Gomez-Ambrosi, Javier ; Pulido, Marina R. ; Russell, Wendy R. ; Imbernon, Monica ; Ross, Ruth A. ; Malagon, Maria M. ; Dieguez, Carlos ; Manuel Fernandez-Real, Jose ; Fruehbeck, Gema ; Nogueiras, Ruben. / The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. In: Diabetes. 2012 ; Vol. 61, No. 2. pp. 281-291.
@article{65e6f21277794a7bb24ed138ad2fd8eb,
title = "The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity",
abstract = "GPR55 is a putative cannabinoid receptor, and l-α-lysophosphatidylinositol (LPI) is its only known endogenous ligand. We investigated 1) whether GPR55 is expressed in fat and liver; 2) the correlation of both GPR55 and LPI with several metabolic parameters; and 3) the actions of LPI on human adipocytes. We analyzed CB1, CB2, and GPR55 gene expression and circulating LPI levels in two independent cohorts of obese and lean subjects, with both normal or impaired glucose tolerance and type 2 diabetes. Ex vivo experiments were used to measure intracellular calcium and lipid accumulation. GPR55 levels were augmented in the adipose tissue of obese subjects and further so in obese patients with type 2 diabetes when compared with nonobese subjects. Visceral adipose tissue GPR55 correlated positively with weight, BMI, and percent fat mass, particularly in women. Hepatic GPR55 gene expression was similar in obese and type 2 diabetic subjects. Circulating LPI levels were increased in obese patients and correlated with fat percentage and BMI in women. LPI increased the expression of lipogenic genes in visceral adipose tissue explants and intracellular calcium in differentiated visceral adipocytes. These findings indicate that the LPI/GPR55 system is positively associated with obesity in humans.",
keywords = "type-2 diabetes-mellitus, human adipose-tissue, cannabinoid receptor, endocannabinoid system, energy-balance, sexual dimorphism, gene-expression, gastric bypass, ovarian-cancer, GPR55",
author = "{Maria Moreno-Navarrete}, Jose and Victoria Catalan and Lauren Whyte and Adenis Diaz-Arteaga and Rafael Vazquez-Martinez and Fernando Rotellar and Rocio Guzman and Javier Gomez-Ambrosi and Pulido, {Marina R.} and Russell, {Wendy R.} and Monica Imbernon and Ross, {Ruth A.} and Malagon, {Maria M.} and Carlos Dieguez and {Manuel Fernandez-Real}, Jose and Gema Fruehbeck and Ruben Nogueiras",
year = "2012",
month = "2",
doi = "10.2337/db11-0649",
language = "English",
volume = "61",
pages = "281--291",
journal = "Diabetes",
issn = "0012-1797",
publisher = "AMER DIABETES ASSOC",
number = "2",

}

TY - JOUR

T1 - The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity

AU - Maria Moreno-Navarrete, Jose

AU - Catalan, Victoria

AU - Whyte, Lauren

AU - Diaz-Arteaga, Adenis

AU - Vazquez-Martinez, Rafael

AU - Rotellar, Fernando

AU - Guzman, Rocio

AU - Gomez-Ambrosi, Javier

AU - Pulido, Marina R.

AU - Russell, Wendy R.

AU - Imbernon, Monica

AU - Ross, Ruth A.

AU - Malagon, Maria M.

AU - Dieguez, Carlos

AU - Manuel Fernandez-Real, Jose

AU - Fruehbeck, Gema

AU - Nogueiras, Ruben

PY - 2012/2

Y1 - 2012/2

N2 - GPR55 is a putative cannabinoid receptor, and l-α-lysophosphatidylinositol (LPI) is its only known endogenous ligand. We investigated 1) whether GPR55 is expressed in fat and liver; 2) the correlation of both GPR55 and LPI with several metabolic parameters; and 3) the actions of LPI on human adipocytes. We analyzed CB1, CB2, and GPR55 gene expression and circulating LPI levels in two independent cohorts of obese and lean subjects, with both normal or impaired glucose tolerance and type 2 diabetes. Ex vivo experiments were used to measure intracellular calcium and lipid accumulation. GPR55 levels were augmented in the adipose tissue of obese subjects and further so in obese patients with type 2 diabetes when compared with nonobese subjects. Visceral adipose tissue GPR55 correlated positively with weight, BMI, and percent fat mass, particularly in women. Hepatic GPR55 gene expression was similar in obese and type 2 diabetic subjects. Circulating LPI levels were increased in obese patients and correlated with fat percentage and BMI in women. LPI increased the expression of lipogenic genes in visceral adipose tissue explants and intracellular calcium in differentiated visceral adipocytes. These findings indicate that the LPI/GPR55 system is positively associated with obesity in humans.

AB - GPR55 is a putative cannabinoid receptor, and l-α-lysophosphatidylinositol (LPI) is its only known endogenous ligand. We investigated 1) whether GPR55 is expressed in fat and liver; 2) the correlation of both GPR55 and LPI with several metabolic parameters; and 3) the actions of LPI on human adipocytes. We analyzed CB1, CB2, and GPR55 gene expression and circulating LPI levels in two independent cohorts of obese and lean subjects, with both normal or impaired glucose tolerance and type 2 diabetes. Ex vivo experiments were used to measure intracellular calcium and lipid accumulation. GPR55 levels were augmented in the adipose tissue of obese subjects and further so in obese patients with type 2 diabetes when compared with nonobese subjects. Visceral adipose tissue GPR55 correlated positively with weight, BMI, and percent fat mass, particularly in women. Hepatic GPR55 gene expression was similar in obese and type 2 diabetic subjects. Circulating LPI levels were increased in obese patients and correlated with fat percentage and BMI in women. LPI increased the expression of lipogenic genes in visceral adipose tissue explants and intracellular calcium in differentiated visceral adipocytes. These findings indicate that the LPI/GPR55 system is positively associated with obesity in humans.

KW - type-2 diabetes-mellitus

KW - human adipose-tissue

KW - cannabinoid receptor

KW - endocannabinoid system

KW - energy-balance

KW - sexual dimorphism

KW - gene-expression

KW - gastric bypass

KW - ovarian-cancer

KW - GPR55

UR - http://europepmc.org/abstract/med/22179809

U2 - 10.2337/db11-0649

DO - 10.2337/db11-0649

M3 - Article

VL - 61

SP - 281

EP - 291

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 2

ER -